结论我院口服降糖药物利用药基本合理。
Conclusion the drug utilization of oral hypoglycemic agents in our hospital is rational on the whole.
同时两组患者均口服降糖药物和胰岛素治疗。
At the same time two groups of patients had oral hypoglycemic drugs and insulin therapy.
两组均根据患者情况选择口服降糖药物控制血糖。
Two groups were treated in oral antidiabetic drug to control blood sugar according to patient's information.
结论2004年北京市销售的4种常用口服降糖药物整体质量较好。
CONCLUSION: the quality of4kinds of common oral antidiabetics in Beijing medicine market in2004is satisfactory on the whole.
目的评价2型糖尿病患者口服降糖药物(OHA)治疗的依从性水平并探讨其影响因素。
Objective to evaluate the compliance of type 2 diabetes (2dm) treated with oral hypoglycemic agents (OHA) and analyze its influence factors.
拜唐苹这一口服降糖药物的良好安全性已经得到广泛验证，而且其餐时服用的给药方式非常方便。
Glucobay is a well established effective oral treatment with an excellent safety profile conveniently taken at mealtimes.
目的：介绍口服降糖药物的种类和主要作用，重点介绍胰岛素抵抗改善药物的作用机制和开发动态。
Objective: To introduce the types and main roles of oral hypoglycemic drugs, emphasizing on the action mechanism and developmental trends of insulin sensitizing agent.
在IMPROVE研究中，27%的患者在此之前未接受过糖尿病治疗，67%的患者仅使用口服降糖药物治疗，6%的患者使用胰岛素治疗(其中部分患者同时使用口服降糖药治疗)。
Overall, 27% of participants had not received prior treatment for their diabetes, 67% were on oral antidiabetic drugs alone, and 6% were receiving insulin with or without oral antidiabetic drugs.
胰岛素促泌剂是目前治疗2型糖尿病的一类主要口服降糖药，是非肥胖及部分肥胖2型糖尿病的一线治疗药物。
Insulin secretagogues presently is not only a kind of major oral hypoglycemic drugs but also the first-line treatment for non-obese and obese type 2 diabetic mellitus(T2DM).
胰岛素促泌剂是目前治疗2型糖尿病的一类主要口服降糖药，是非肥胖及部分肥胖2型糖尿病的一线治疗药物。
Insulin secretagogues presently is not only a kind of major oral hypoglycemic drugs but also the first-line treatment for non-obese and obese type 2 diabetic mellitus(T2DM).
应用推荐